Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Andreas Wollenberg
ResearcherPublications, citations & collaboration network
Andreas Wollenberg is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 570 works, 29,469 citations, an h-index of 81 and an i10-index of 278.
570
Works
29,469
Citations
81
h-index
278
i10-index
How has Andreas Wollenberg's publication output changed over time?
ScholarIQpublication output · 1992–2022
Output grew0% over the shown period — from 1 works in 1992 to 1 in 2022.
1
1
2
1
2
1
3
1
19922012201620172018201920202022
What are the most-cited papers on Andreas Wollenberg?
ScholarIQmost cited works
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L. Simpson, Thomas Bieber, Emma Guttman‐Yassky, Lisa A. Beck, Andrew Blauvelt, Michael J. Cork, Jonathan I. Silverberg, Mette Deleuran, Yoko Kataoka, J.‐P. Lacour, Külli Kingo, Margitta Worm, Yves Poulin, Andreas Wollenberg, Yuhwen Soo, Neil M.H. Graham, Gianluca Pirozzi, Bolanle Akinlade, Heribert Staudinger, Vera Mastey, Laurent Eckert, Abhijit Gadkari, Neil Stahl, George D. Yancopoulos, Marius Ardeleanu
New England Journal of Medicine. 20162,067 CitationsOPEN ACCESS
Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I
Andreas Wollenberg, S. Barbarot, Thomas Bieber, Stéphanie Christen‐Zaech, Mette Deleuran, A. Fink‐Wagner, Uwe Gieler, Giampiero Girolomoni, S. Lau, Antonella Muraro, Magdalena Czarnecka‐Operacz, T. Schäfer, Peter Schmid‐Grendelmeier, Dagmar Simon, Zsuzsanna Szalai, Jacek C. Szepietowski, Alain Taı̈eb, Antonio Torrelo, Thomas Werfel, Johannes Ring
Journal of the European Academy of Dermatology and Venereology. 20181,183 CitationsOPEN ACCESS
Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II
Andreas Wollenberg, S. Barbarot, Thomas Bieber, Stéphanie Christen‐Zaech, Mette Deleuran, A. Fink‐Wagner, Uwe Gieler, Giampiero Girolomoni, S. Lau, Antonella Muraro, Magdalena Czarnecka‐Operacz, T. Schäfer, Peter Schmid‐Grendelmeier, Dagmar Simon, Zsuzsanna Szalai, Jacek C. Szepietowski, Alain Taı̈eb, Antonio Torrelo, Thomas Werfel, Johannes Ring
Journal of the European Academy of Dermatology and Venereology. 2018689 CitationsOPEN ACCESS
Guidelines for treatment of atopic eczema (atopic dermatitis) Part I
Johannes Ring, A. Alomar, Thomas Bieber, Mette Deleuran, A. Fink‐Wagner, C. Gelmetti, Uwe Gieler, Jasna Lipozenčić, Thomas A. Luger, A. P. Oranje, T. Schäfer, Thomas Schwennesen, Stefania Seidenari, Dagmar Simon, Sonja Ständer, Georg Stingl, S. Szalai, Jacek C. Szepietowski, Alain Taı̈eb, Thomas Werfel, Andreas Wollenberg, Ulf Darsow
Journal of the European Academy of Dermatology and Venereology. 2012683 Citations
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky, Margitta Worm, Charles Lynde, J.‐P. Lacour, Lynda Spelman, Norito Katoh, Hidehisa Saeki, Yves Poulin, Aleksandra Lesiak, Leon Kircik, S.H. Cho, Pedro Herranz, Michael J. Cork, Ketty Peris, Louise Abildgaard Steffensen, B K Bang, Alexandra Kuznetsova, T.N. Jensen, Marie Louise Østerdal, Eric L. Simpson, the ECZTRA 1 and ECZTRA 2 study investigators
British Journal of Dermatology. 2020612 CitationsOPEN ACCESS
Related on ScholarIQ
University Hospital Augsburg
Institution
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Paper
Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I
Paper
Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II
Paper
Guidelines for treatment of atopic eczema (atopic dermatitis) Part I
Paper
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
Paper